Vizamyl
Payments companies reported to CMS as associated with Vizamyl. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vizamyl, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vizamyl
These are the largest totals companies reported as associated with Vizamyl. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Suzanne Bash | Los Angeles, CA | Diagnostic Radiology | $26,930.00 |
| Phillip Kuo | Duarte, CA | Diagnostic Radiology | $6,776.00 |
| Giuseppe Esposito | Washington, DC | Nuclear Medicine | $5,000.00 |
| Jamieson Bourque | Charlottesville, VA | Cardiovascular Disease | $2,500.00 |
| Philip Kuo | Kailua, HI | Allergy & Immunology | $2,464.00 |
| Melissa Budahazy | Glenview, IL | Nurse Practitioner | $2,432.83 |
| Marwan Sabbagh | Phoenix, AZ | Neurology (Psychiatry & Neurology) | $2,000.00 |
Prescribed Vizamyl?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.